Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: DRUG: MSB0010718C
Sponsor: Istituto Oncologico Veneto IRCCS
Collaborators: University of Padova|Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche